We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In a recent Chief Counsel Memorandum (“CCM”), the Internal Revenue Service (the “IRS”) concluded (contrary to an established industry custom) that attorney fees incurred for investigatory patent research and to defend actions for patent infringement in connection with the filing of abbreviated new drug applications (“ANDAs”) were not deductible and instead must be capitalized
